The ability to prescribe controlled substances based on telehealth patient visits was set to expire when the COVID-19 Public Health Emergency ends on Thursday, May 11th.
The U.S. Drug Enforcement Administration (DEA) initially issued two proposed rules establishing new policies for controlled substance prescriptions based on telehealth visits, one for buprenorphine and one for other controlled substances.
The AMA weighed in on the policy with multiple arms of the Biden administration, including the DEA as well as Rahul Gupta, MD, the Director of the White House Office of National Drug Control Policy.
After receiving more than 38,000 comment letters, however, the DEA has decided to extend the same policies that have been in place during COVID for an additional 6 months, until November 11, 2023.
Florida Women in Nephrology Chair
FSN President
Print Page
Email to a Friend